The Impact of Molecular Testing on Treatment Choices for NSCLC

Opinion
Video

A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.

Video content above is prompted by the following:

  • What factors make this patient an ideal candidate for EGFR inhibitor therapy?
  • How important is biomarker testing in guiding treatment choices for EGFR+ NSCLC?
  • Can you share your approach to testing for EGFR mutations, and any barriers encountered, especially in community settings?
Recent Videos
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Two experts are featured in this series.
Related Content
No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Non-Viral Gene Therapy Displays Feasibility in EGFR-Mutated NSCLC

Roman Fabbricatore
November 24th 2025
Article

No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.

FDA Approves Sevabertinib in Non-Squamous NSCLC

Tim Cortese
November 19th 2025
Article

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Duality Biotherapeutics entered an exclusive license agreement with Avenzo Therapeutics in January 2025.

AVZO-1418/DB-1418 Earns FDA Fast Track Designation For EGFR-Mutated NSCLC

Roman Fabbricatore
November 14th 2025
Article

The EGFR/HER3 bispecific ADC is being evaluated in an open-label phase 1/2 study to assess its safety, tolerability, and activity in advanced solid tumors.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.